Recursion Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
05/08/2025 14:32
Recursion Pharmaceuticals Inc RXRX.OQ reported a quarterly adjusted loss of 41 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -40 cents. The mean expectation of six analysts for the quarter was for a loss of 35 cents per share. Wall Street expected results to range from -40 cents to -29 cents per share. Revenue rose 33.3% to $19.22 million from a year ago; analysts expected $15.43 million. Recursion Pharmaceuticals Inc's reported EPS for the quarter was a loss of 41 cents. The company reported a quarterly loss of $171.9 million. Recursion Pharmaceuticals Inc shares had risen by 14.6% this quarter and lost 14.2% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 22.7% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy." Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $6.50, about 10.8% above its last closing price of $5.80 This summary was machine generated from LSEG data August 5 at 01:32 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.35 | -0.41 | Missed |
| Mar. 31 2025 | -0.52 | -0.50 | Beat |
| Dec. 31 2024 | -0.43 | -0.53 | Missed |
| Sep. 30 2024 | -0.35 | -0.34 | Beat |
Recent news on Recursion Pharmaceuticals
See all newsBrief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million